December 10, 2003 (PDF) - Micrologix Reports Second Quarter Fiscal Year 2004 Financial Results

December 9, 2003 (PDF) - Micrologix Licenses Hepatitis B Compound to Spring Bank Technologies - US$2.6 Million NIH Grant Funding Approved for Development

November 17, 2003 (PDF) - Micrologix Reports Efficacy From Phase IIb Acne Study - Statistically Significant Data Validates Anti-Acne Properties of MBI 594AN

September 30, 2003 (PDF) - Micrologix Completes MBI 594AN Phase IIb Acne Trial

September 22, 2003 (PDF) - Micrologix and Fujisawa to Further Assess MBI 226 Regulatory and Market Options

September 18, 2003 (PDF) - Micrologix to Present at UBS Global Life Sciences Conference

September 9, 2003 (PDF) - Micrologix Reports First Quarter Fiscal Year 2004 Financial Results

July 23, 2003 (PDF) - Micrologix Reports Phase III Trial Results of MBI 226 - Statistical Superiority Not Achieved in Preventing Bloodstream Infections

July 10, 2003 (PDF) - Micrologix Reports Fourth Quarter 2003 Financial Results

June 24, 2003 (PDF) - Micrologix Attracts Industry Leaders to Newly Established Scientific Advisory Board

May 12, 2003 (PDF) - Micrologix Provides Guidance on Timing of MBI 226 Phase 3 Results

March 12, 2003 (PDF) - Micrologix Reports Third Quarter 2003 Financial Results

February 3, 2003 (PDF) - Micrologix Completes Full Enrollment in Pivotal Phase III Trial of MBI 226

January 28, 2003 (PDF) - Micrologix Advances MBI 594AN for the Treatment of Acne